Testing a new cell therapy for severe lupus and scleroderma

Plain-English translation of NCT06822881 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This clinical trial is testing a new treatment called CT1190B CAR-T cell therapy for people with severe lupus or systemic sclerosis (a disease causing skin and organ hardening) that has not improved with standard medications. CT1190B is a type of cell therapy where special immune cells are designed to help calm down the overactive immune system. The study will look at whether this treatment is safe and how well it works.

Many people with severe lupus and scleroderma don't get better even after trying multiple standard treatments, and they continue to suffer from serious symptoms and organ damage. This trial is exploring whether this new medication could offer hope to patients who haven't had success with existing options.

Do you qualify?

You likely qualify if…

you are between 18 and 60 years old
you have been diagnosed with either moderate to severe lupus lasting at least 6 months, or severe scleroderma with lung involvement
you have already tried standard lupus or scleroderma treatments for at least 3 months without adequate improvement
you have no active infections or major organ problems (your kidneys, liver, heart, and lungs are functioning reasonably well)
if you can become pregnant, you are willing to use birth control during the study
you are willing to provide informed consent and understand the study requirements

You likely don't qualify if…

you have an active infection in the two weeks before screening
you are pregnant or breastfeeding
you have severe heart, kidney, or liver disease
you have a low blood cell count that would make the treatment unsafe
you have other serious health conditions that would make participation risky

What participation looks like

If you join this study, you will receive an infusion of CT1190B cells—specially engineered immune cells designed to help control your lupus or scleroderma. The study will monitor you closely with regular visits to check your safety and how well the treatment is working, including blood tests and assessments of your symptoms and organ function. You will be followed for a period of time to see if the medication helps reduce disease activity and improve your quality of life.

AI-generated summary from trial data · Jun 5, 2026 · Not medical advice

Trial locations(1 site)

China

Beijing GoBroad Hospital, Beijing, Beijing Municipality